During the spring, Chief Technology Officer Viktor Granskog along with product engineers Lola Opande and Ram Shadher, have been stationed to perform Bonevolent™ AdhFix manufacturing in the cleanroom environment medical facility. This crucial step will enable the execution of design validation activities of Bonevolent™ AdhFix, a customizable composite implant that can be tailored for fracture fixation.
The team has worked hard to coordinate production planning, manufacture all necessary components in a cleanroom environment while documenting all steps in accordance with our QMS, and successfully filled nearly 2000 syringes and vials for the AdhFix kits in a short period of time. It is inspiring to see how dedicated the team is and I am extremely proud of the excellent execution. The team has delivered on key milestones with remarkable precision. Amazing!, says CEO Evelina Mikaelson.
The work has been performed with support from Swelife Medtech4Health and Eureka Eurostars via Vinnova - Sweden's Innovation Agency.
For more information, please contact:
Evelina Mikaelson
CEO Biomedical Bonding AB
Phone: +46 763 422 824
Email: Evelina.mikaelson@biomedicalbonding.com
Homepage: www.biomedicalbonding.com
About Biomedical Bonding AB
Biomedical Bonding AB is a Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.